InvestorsHub Logo
Post# of 1647
Next 10
Followers 12
Posts 283
Boards Moderated 0
Alias Born 11/03/2011

Re: WHELANer post# 1332

Tuesday, 08/08/2017 3:02:12 PM

Tuesday, August 08, 2017 3:02:12 PM

Post# of 1647
Woo hoo....you Girls Gone Giddy yet? ( GG&G )

The migraine news is kinda comical with the name of Dr Barry Eppley. He conducted the sham study on Allay with Dr. Sheena Kong who was Joe Noel's girlfriend that he met on a dating site through a matchmaker back in 2009. lol
Lot's of complaints from participants in that study not getting paid their $50.00 promised by Joe who was assisting Sheena on supposedly Biel's behalf. I say supposedly because Joe bought the rights to Allay for the US and tried to get the rights for Japan but ran into a roadblock.

It seems the market holds no weight to this news and it shows in the share price dropping as it has done for years with most every PR. Even if the study is completed what is going to increase shareholder value?

SO if you're sick of the 7's then welcome back to the 6's. The 6's-7's are a fair market value as it is double the 3's (with no FDA clearance). Full FDA OTC clearance would give this a .0011-12 market value with the current CEO and staff in place. With a reputable company and big name partner ( with deep pockets ) showing interest and coming aboard then the potential market value would increase substantially to .01 -.02 cents quickly and continue to rise.

Let's hope there is something motivating in the 2nd quarterly report. Let's also hope that the anticipated shareholder letter doesn't just rehash old news and Andy's wishful thinking and forward looking dreams which takes a lot of time and dilution to reach.

In the mean time other well established companies are moving forward within the neuromodulation / SWT healing and pain relief space.

Do your own DD.

GLTA


Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.